We are live on ! Find out more
BIOTU

Biotech Acquisition Company Unit
BIOTU

Delisted

BIOTU was delisted on the 2nd of February, 2023.

Back to rankings

59 hedge funds and large institutions have $118M invested in Biotech Acquisition Company Unit in 2021 Q1 according to their latest regulatory filings, with 59 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
59
Holders Change
+59
Holders Change %
–
% of All Funds
1.04%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
59
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Aristeia Capital
Connecticut
+$11.8M
2
HIM
HGC Investment Management
Ontario, Canada
+$11.3M
3
GCL
Glazer Capital LLC
New York
+$10.8M
4
BCM
BlueCrest Capital Management
Jersey
+$10.3M
5
LA
Linden Advisors
New York
+$6.98M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Aristeia Capital
Connecticut
$11.4M +$11.8M +1,149,010 New
HIM
2
HGC Investment Management
Ontario, Canada
$10.9M +$11.3M +1,101,900 New
GCL
3
Glazer Capital LLC
New York
$10.4M +$10.8M +1,054,547 New
BCM
4
BlueCrest Capital Management
Jersey
$9.89M +$10.3M +1,000,000 New
LA
5
Linden Advisors
New York
$6.71M +$6.98M +678,849 New
SRCM
6
Sage Rock Capital Management
New York
$5.67M +$5.9M +573,800 New
PC
7
Periscope Capital
Ontario, Canada
$4.91M +$5.11M +496,846 New
DCM
8
DG Capital Management
New York
$4.45M +$4.63M +450,000 New
MF
9
Magnetar Financial
Illinois
$4.33M +$4.5M +437,893 New
RCM
10
Radcliffe Capital Management
Pennsylvania
$4.01M +$4.17M +405,900 New
Nomura Holdings
11
Nomura Holdings
Japan
$3.98M +$4.12M +400,137 New
KSCM
12
Kamunting Street Capital Management
Florida
$3.14M +$3.27M +317,924 New
DKCM
13
Davidson Kempner Capital Management
New York
$2.96M +$3.09M +300,000 New
Deutsche Bank
14
Deutsche Bank
Germany
$2.73M +$2.84M +275,714 New
KC
15
Kepos Capital
New York
$2.62M +$2.72M +264,400 New
ACA
16
Arena Capital Advisors
California
$1.98M +$2.06M +200,000 New
CCM
17
Context Capital Management
California
$1.98M +$2.06M +200,000 New
PSAMP
18
P. Schoenfeld Asset Management (PSAM)
New York
$1.98M +$2.06M +200,000 New
WAM
19
Wolverine Asset Management
Illinois
$1.93M +$2M +194,844 New
SCM
20
Saba Capital Management
New York
$1.78M +$1.85M +179,960 New
JP Morgan Chase
21
JP Morgan Chase
New York
$1.48M +$1.54M +149,620 New
Millennium Management
22
Millennium Management
New York
$1.41M +$1.46M +142,280 New
CIM
23
Cowen Investment Management
New York
$1.24M +$1.29M +125,000 New
TI
24
Telemetry Investments
New York
$1.04M +$1.08M +105,000 New
HP
25
Hound Partners
New York
$989K +$1.03M +100,000 New
1
2 3

BIOTU Hedge Fund Activity: Q1 2021 in Review

59 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Biotech Acquisition Company Unit (BIOTU) for Q1 2021, worth a combined $118M.

Buyers outnumbered sellers: 59 funds opened new BIOTU positions and 0 closed out — a net gain of 59 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Aristeia Capital, opening a new position worth an estimated $11.8M.

  • 59 institutional investors held Biotech Acquisition Company Unit (BIOTU) as of Q1 2021, up from 0 in Q4 2020.
  • Funds reported $118M of Biotech Acquisition Company Unit stock for Q1 2021.
  • 59 funds opened new Biotech Acquisition Company Unit positions in Q1 2021 and 0 closed out, a net change of +59 holders.
  • The largest Biotech Acquisition Company Unit buyer in Q1 2021 was Aristeia Capital, an estimated $11.8M added.

Based on aggregated 13F filings for Q1 2021.